A Switch Study of BMS-337039 in Schizophrenic Out-patients

PHASE4CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Schizophrenia
Interventions
DRUG

Aripiprazole

Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.

DRUG

Aripiprazole

Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.

Trial Locations (72)

Unknown

Local Institution, Hall/Tirol

Local Institution, Vienna

Local Institution, Bruges

Local Institution, Brussels

Local Institution, Diest

Local Institution, Halle

Local Institution, Sint-Denijs-Westrem

Local Institution, Stokrooie

Local Institution, Havířov

Local Institution, Olomouc

Local Institution, Prague

Local Institution, Přerov

Local Institution, Aubagne

Local Institution, Bordeaux

Local Institution, Brumath

Local Institution, Château-Gontier

Local Institution, Clermont-Ferrand

Local Institution, Dijon

Local Institution, Dommartin-lès-Toul

Local Institution, Fains-Véel

Local Institution, Hénin-Beaumont

Local Institution, Le Pecq

Local Institution, Lyon

Local Institution, Poitiers

Local Institution, Reims

Local Institution, Roubaix

Local Institution, Toulon

Local Institution, Toulouse

Local Institution, Achim

Local Institution, Bochum

Local Institution, Cologne

Local Institution, Ellwangen

Local Institution, Hattingen

Local Institution, Neurnberg

Local Institution, Osnabrück

Local Institution, Ostfildern

Local Institution, Witten

Local Institution, Athens

Local Institution, Chania-Crete

Local Institution, Corfu

Local Institution, Leros

Local Institution, Thessaloniki

Local Institution, Tripoli

Local Institution, Baja

Local Institution, Eger

Local Institution, Esztergom

Local Institution, Kistarcsa

Local Institution, Pécs

Local Institution, Sopron

Local Institution, Sestri Ponente

Local Institution, Aosta

Local Institution, Bolzano

Local Institution, Foggia

Local Institution, L’Aquila

Local Institution, Milan

Local Institution, Roggiano Gravina (Cs)

Local Institution, Roma

Local Institution, Terrassa

Local Institution, Barcelona

Local Institution, Elche (Alicante)

Local Institution, Langreo-Asturias

Local Institution, Madrid

Local Institution, Murcia

Local Institution, Oviedo

Local Institution, Salamanca

Local Institution, Valencia

Local Institution, Zamora

Local Institution, Newport

Local Institution, South Wales

Local Institution, Hull

Local Institution, Dundee

Local Institution, Haywards Health

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT00232687 - A Switch Study of BMS-337039 in Schizophrenic Out-patients | Biotech Hunter | Biotech Hunter